Table 25Outcomes by length of time interval in stable population assessing morbidity for NT-proBNP

Outcome MeasuresFollowup Months
123456789101112131415161718192021222324
All-cause morbidity
Pfister,347 2011
Schou,281 200228->
Cardiovascular morbidity
Berger,4 2010
Mikkelsen,283 2006
Michowitz,332 2007
Bruch,319 2008
Masson/Cohn,286 2006/2001
Rothenburger,276 2004
George,290 2005
Wedel,309 200932->
Kubanek,308 200939->
Charach,302 200944->

XI vertical line indicates intermittent endpoint measurement

*

mean;

**

median;

->study duration and endpoint greater than 24 months

From: Results

Cover of Use of Natriuretic Peptide Measurement in the Management of Heart Failure
Use of Natriuretic Peptide Measurement in the Management of Heart Failure [Internet].
Comparative Effectiveness Reviews, No. 126.
Balion C, Don-Wauchope A, Hill S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.